Zag Bio has launched its first human study of ZAG-101, an innovative therapy aiming to modify the disease process in type 1 diabetes by targeting the immune system through the thymus, marking its transition into clinical-stage development.
Zag Bio said it has begun clinical testing of ZAG-101, its lead experimental treatment for type 1 diabetes, marking the Cambridge, Massachusetts-based company’s move into human trials. The first study, called LANTERN, will assess safety, tolerability, pharmacokinetics and pharmacodynamics, while also looking for early signs that the drug may help preserve the body’s own insulin-producing beta cells. The company’s website says the programme is aimed at people newly diagnosed with type 1 diabetes or those at high risk of developing the condition.
Type 1 diabetes is an autoimmune disease in which the immune system destroys beta cells in the pancreas, forcing patients to rely on insulin for survival. Zag Bio says ZAG-101 is designed to deliver insulin-related material to the thymus, the organ that helps train immune cells to avoid attacking the body’s own tissues. In theory, the treatment is intended to encourage the growth of regulatory T cells, which can help restrain harmful immune responses, while reducing cells that drive the disease.
Chief executive Jason Cole said the move into the clinic turns Zag Bio into a clinical-stage company and represents an important test of its thymus-targeted approach. Chief medical officer Jan Hillson said the trial is intended to provide the first human data on whether the treatment can affect the underlying autoimmunity in type 1 diabetes, rather than simply managing blood sugar. Those comments echo the company’s earlier descriptions of ZAG-101 as a disease-modifying therapy rather than a symptomatic treatment.
The initial trial will enrol adults with stage 3 type 1 diabetes and test both single and repeated doses, with intravenous and subcutaneous delivery planned. Zag Bio said the study will also examine C-peptide, a marker of the body’s own insulin production, alongside immune assays meant to track regulatory and effector T-cell responses. The company plans to begin in Australia and Europe, then expand to adolescents and possibly to earlier stages of disease if the programme shows enough promise. Industry reporting earlier this year also indicated that the treatment programme was moving towards clinical development in the second half of 2026, following a manufacturing partnership to support ZAG-101’s progression.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
